Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Approval of ALKS 3831 looks likely after Friday’s positive panel vote, but sales might disappoint.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.